von Willebrand Diagnostic Interpretive Panel (Limited)
Test Mnemonic
VWFPR
CPT Codes
- 85730 - QTY (1)
- 85240 - QTY (1)
- 85245 - QTY (2)
- 85246 - QTY (1)
- 85610 - QTY (1)
- 85247 - QTY (1)
- 83520 - QTY (1)
- 85390 - QTY (1)
Includes
- VWF:GpIbM Activity
- Prothrombin Time (PT)
- APTT
- Ristocetin Cofactor
- Collagen Binding Assay(CBA)
- Factor VIII assay (FVIII)
- von Willebrand Factor Antigen (VWF)
- CBA/VWF Ratio
- Ristocetin Cofactor/VWF Ratio
- FVIII/VWF Ratio
- von Willebrand Multimer
Performing Laboratory
Cleveland Clinic Laboratories
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 6 mL | Plasma | Sodium citrate (Lt. Blue) | Centrifuge, aliquot and freeze ASAP. | Centrifuge samples; Aliquot plasma into a separate tube and label with Epic Beaker labels. Specimens should be frozen (-20C or colder). |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 3 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | Unacceptable |
| Refrigerated | Unacceptable |
| Frozen | -20° C stable for 2 weeks or -70° C stable for 6 months |
Days Performed
Mon - Fri
Turnaround Time
10 days
Methodology
| Name | Description |
|---|---|
| Aggregation | |
| Clotting Assay | |
| Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Latex Immunoassay (LIA) |
Reference Range
| Activated PTT | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Days | 1 Days | Normal | 27.1 - 43.7 | sec | 2 Days | 5 Days | Normal | 22.0 - 48.0 | sec | 6 Days | 30 Days | Normal | 22.1 - 44.3 | sec | 1 Months | 3 Months | Normal | 20.8 - 40.2 | sec | 4 Months | 11 Months | Normal | 24.3 - 34.4 | sec | 1 Years | 99 Years | Normal | 23.0 - 32.4 | sec | Years | 99 Years | Urgent | > 100.0 | sec | Years | 99 Years | Critical | EXTREMELY ABNORMAL RESULT. No clot detected at 320 seconds. Refer to anticoagulation nomogram for further actions. |
| CBA/VWF Ratio | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | >0.6 | . | |||
| Factor VIII/VWF Ratio | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | >0.5 | . | |||
| Factor VIII:C Assay | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| ~ | Days | 2 Days | Urgent | <=4 | % | ~ | 2 Days | 6 Days | Urgent | <=4 | % | ~ | 30 Days | 4 Months | Urgent | <=4 | % | ~ | 6 Days | 30 Days | Urgent | <=4 | % | ~ | 1 Years | 6 Years | Urgent | <=4 | % | ~ | 11 Years | 17 Years | Urgent | <=4 | % | ~ | 17 Years | 999 Years | Urgent | <=4 | % | ~ | 6 Years | 11 Years | Urgent | <=4 | % | ~ | 4 Months | 1 Years | Urgent | <=4 | % |
| INR | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| ~ | Days | 2 Days | Urgent | >=5.1 | ~ | 2 Days | 6 Days | Urgent | >=5.1 | ~ | 6 Days | 1 Months | Urgent | >=5.1 | ~ | Urgent | >9999.0 | ~ | 1 Years | 999 Years | Urgent | >=5.1 | ~ | Days | 2 Days | Urgent | >=5.1 | ~ | 1 Months | 4 Months | Urgent | >=5.1 | ~ | 4 Months | 1 Years | Urgent | >=5.1 | ~ | 2 Days | 6 Days | Urgent | >=5.1 | ~ | 6 Days | 1 Months | Urgent | >=5.1 | ~ | 1 Years | 999 Years | Urgent | >=5.1 | ~ | 1 Months | 4 Months | Urgent | >=5.1 | ~ | 4 Months | 1 Years | Urgent | >=5.1 | ~ | Critical | >=4.5 | ~ | Critical | >4.9 |
| Ristocetin Co-Factor | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Years | 99 Years | Normal | 42-146 | % | |
| Ristocetin Cofactor/VWF Ratio | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | >0.5 | . | |||
| von Willebrand Diagnostic Interpretive Panel | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Refer to reference ranges of individual test components. Reference ranges for calculated ratios: | |||||
| VWF:GpIbM Activity | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Normal | 44-156 | % |
Special Info
Sample must be accompanied by the completed Clinical History Form for Hemostasis and Thrombosis Evaluation. If test results in panel are abnormal, additional testing may be ordered and billed. These tests include FIX (85250), FXI (85270), FXII (85280), FXIII Antigen (85290), Bethesda Inhibitor (85335), FVIII Chromogenic (85240), DRVVT (85613), Staclot (85730, 85732), PTT MIX (85730), and PNP (85597).
Clinical Info
Evaluation of bleeding disorders caused by abnormalities of von Willebrand factor, especially those accompanied by prolonged PTT and bleeding time. Differentiation of Hemophilia A (Factor VIII deficiency) from von Willebrand disease.